Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Fatma F S, Ebeid"'
Autor:
Hany M. Dabbous, Manal H. El-Sayed, Gihan El Assal, Hesham Elghazaly, Fatma F. S. Ebeid, Ahmed F. Sherief, Maha Elgaafary, Ehab Fawzy, Sahar M. Hassany, Ahmed R. Riad, Mohamed A. TagelDin
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Abstract Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases. It was randomized-
Externí odkaz:
https://doaj.org/article/2801616f9f1a4ec286b074ac78b065d0
Autor:
Hany M. Dabbous, Manal H. El‑Sayed, Gihan El Assal, Hesham Elghazaly, Fatma F. S. Ebeid, Ahmed F. Sherief, Maha Elgaafary, Ehab Fawzy, Sahar M. Hassany, Ahmed R. Riad, Mohamed A. TagelDin
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/4b565f65ac4a46f0bd15948e52f78885
Autor:
Mohamed Elbahnasawy, Rehab Badawi, Shaimaa Soliman, Manal H El-Sayed, Hany Dabbous, Ahmed F Sherief, Fatma F S Ebeid, Mohamed Awad Tageldin, Sherief Abd-Elsalam, Mohamed Samir Abd El Ghafar
Publikováno v:
Archives of Virology. 166:949-954
No specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID- 19 w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f9e91f102d630f87f36c8f07fa645b48
https://doi.org/10.1007/s00705-021-04956-9
https://doi.org/10.1007/s00705-021-04956-9
Autor:
Fatma F S Ebeid, Manal H El-Sayed, Gihan El Assal, Ahmed R Riad, Sahar M Hassany, Hany Dabbous, Hesham Elghazaly, Mohamed Awad Tageldin, Maha Elgaafary, Ahmed F Sherief, Ehab Fawzy
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-1 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-1 (2021)
Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases. It was randomized-controlle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5309ec6bc940720e07324d7b73743dd0
https://pubmed.ncbi.nlm.nih.gov/33790308
https://pubmed.ncbi.nlm.nih.gov/33790308
Autor:
Marwa Ramadan, Shaimaa Elsayed, Hala Hafez, Asmaa A. Mahmoud, Doaa Fattuh, Ashraf Omar, Fatmaelzahra Hassan, Amany Mansour, Moshira H. Sabry, Manal H El-Sayed, Samia A. Girgis, Sahar Kandil, Iman Afifi, Amira Reda, Aya Mostafa, Mahmoud El-Meteini, Fatma F S Ebeid, Petra Habeb, Ossama Mansour, Hoda Ezzelarab, Mostafa Yosef, Saly Saber, Ayman Saleh
Publikováno v:
International Journal of Epidemiology
Background The scale of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among health care workers (HCWs), particularly in resource-limited settings, remains unclear. To address this concern, universal (non-symptom-based) screen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfa1b369cd1fc00cecb7c75124d123fb
Autor:
Hany M, Dabbous, Manal H, El-Sayed, Gihan, El Assal, Hesham, Elghazaly, Fatma F S, Ebeid, Ahmed F, Sherief, Maha, Elgaafary, Ehab, Fawzy, Sahar M, Hassany, Ahmed R, Riad, Mohamed A, TagelDin
Publikováno v:
Scientific reports. 11(1)
Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases. It was randomized-controlle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ade280940d6db04ee480c078e1562098
https://pubmed.ncbi.nlm.nih.gov/34537808
https://pubmed.ncbi.nlm.nih.gov/34537808
Autor:
Manal H El-Sayed, Maggie M. Abbassi, Mohamed Hassany, Samar F. Farid, Mogeb M Al-Nahari, Fatma F S Ebeid
Publikováno v:
Antiviral therapy. 25(2)
Background Daclatasvir has potent antiviral activity against HCV infection when used in combination with sofosbuvir, however, its pharmacokinetics have not been described in adolescents. The aim is to determine the pharmacokinetic parameters of dacla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9d109d172cee3859fc67ae593d7c44c
https://pubmed.ncbi.nlm.nih.gov/32367815
https://pubmed.ncbi.nlm.nih.gov/32367815
Autor:
Manal H El-Sayed, Hany Dabbous, Mohamed Elbahnasawy, Mohamed Awad Tageldin, Shaimaa Soliman, Rehab Badawi, Fatma F S Ebeid, Mohamed Samir Abd El Ghafar, Ahmed F Sherief, Sherief Abd-Elsalam
Publikováno v:
Archives of Virology
No specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID- 19 w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9355746565e6d31d1bba4e1bf8adfec
https://doi.org/10.1007/s00705-021-05307-4
https://doi.org/10.1007/s00705-021-05307-4